Alzheimer's Archives

News and Trends 5 Jan 2023

2023 Editorial Calendar updated

Each month here at Labiotech.eu, we produce a special newsletter. While still news-related, these special editions are an opportunity to take a deeper look at topics of interest. It also allows us to focus on some of the special awareness days – of which there are many – associated with health and the life sciences. […]

January 5, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 22 Dec 2022

Watch: Norway’s Pre Diagnostics looks to early detection of Alzheimer’s

Pre Diagnostics AS is a new Norwegian company developing and commercializing an innovative and effective diagnostic test for Alzheimer’s disease (AD). Founded by an experienced biotech team, Pre Diagnostics owns the licensed rights to a patent-protected new diagnostic test from the Norwegian university hospital AHUS. The company said it will pursue cost-efficient product development with […]

December 22, 2022 - 1 minutemin - By Jim Cornall

News and Trends 30 Nov 2022

‘Best hope yet’ as results from Alzheimer’s drug trial reveal huge step forward

A huge step forward in dementia research has been hailed a truly historic moment by researchers working to find a cure for people with Alzheimer’s Disease. This is the first time a drug being trialed, lecanemab, has shown a reduction in the disease in the brain while slowing memory decline. Dr Susan Kohlhaas, director of […]

November 30, 2022 - 6 minutesmins - By Liza Laws

News and Trends 30 Nov 2022

bit.bio expands portfolio for drug discovery in neurodegenerative and neurological diseases

Cell coding company bit.bio has made three additions to its product portfolio: ioGlutamatergic Neurons MAPT N279K and ioGlutamatergic Neurons MAPT P301S disease models, and early access to its ioGABAergic Neurons. This expands bit.bio’s central nervous system (CNS) portfolio to four disease models and three cell types. bit.bio’s cell products are reprogrammed from human induced pluripotent […]

November 30, 2022 - 3 minutesmins - By Jim Cornall

Ulrich dauer vivoryon alzheimers disease

Interview 23 Nov 2022

What recent mixed clinical results can teach about Alzheimer’s disease

2022 has provided mixed fortunes for companies aiming to slow Alzheimer’s disease. Ulrich Dauer, CEO of the German biotech Vivoryon, explains the lessons these events provide. The quest for a treatment to slow the progression of Alzheimer’s disease has endured decades of disappointments. The most common treatment strategy — clearing up harmful deposits, or “plaques,” […]

November 23, 2022 - 7 minutesmins - By Jonathan Smith

News and Trends 8 Nov 2022

Study shows enhanced drug delivery to the brain

In a study recently published in the journal Nature Biomedical Engineering, Japanese researchers used a method called “lasso-grafting” to design therapeutics with enhanced longevity and brain penetration. Cell growth and repair are stimulated by biomolecules known as cytokines and growth factors. Unfortunately, delivering adequate concentrations of these molecules to the brain for treating neurological conditions […]

November 8, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 20 Oct 2022

Tiziana Life Sciences looks to phase 1 trial for intranasal Alzheimer’s drug

Tiziana Life Sciences Ltd. says it plans to submit an investigational new drug (IND) application for a phase 1 trial of intranasal foralumab in Alzheimer’s disease patients. It comes after the company received an affirmative written response from the FDA on a pre-investigational new drug application (PIND). Tiziana plans on filing the IND for Alzheimer’s […]

October 20, 2022 - 3 minutesmins - By Jim Cornall

More News! 10 Oct 2022

Positive data indicates likely therapeutic effect of Alzheimer’s drug

Positive phase 2a clinical data from an Alzheimer’s disease (AD) biomarker study, has been announced today (October 10). Actinogen Medical Limited shared the news that its study validates its planned program for Xanamem, a potential drug for the disease. The biomarker study was conducted in 72 patients with available blood biomarker samples from the prior […]

October 10, 2022 - 3 minutesmins - By Liza Laws

News and Trends 7 Oct 2022

Japanese scientists find way to detect characteristic of Alzheimer’s disease from blood samples

Researchers from Hokkaido University in Japan and Toppan have developed a method to detect build-up of amyloid β in the brain, a characteristic of Alzheimer’s disease, from biomarkers in blood samples. Alzheimer’s disease is a neurodegenerative disease, characterized by a gradual loss of neurons and synapses in the brain. One of the primary causes of […]

October 7, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 29 Sep 2022

Human cells can now help scientists accelerate cure for neurodegenerative diseases

Cell products providing a scalable source of human cells can now help scientists study neurogenerative diseases in human context. UK-based, cell-coding company, bit.bio announced the expansion to its portfolio today (September 29) with disease model, ioGlutamatergic Neurons TDP-43 and early access to its ioMicroaglia cell product. Despite research efforts and funding, bit.bio says the development […]

September 29, 2022 - 3 minutesmins - By Liza Laws

More News! 29 Sep 2022

Positive results from Eisai and Biogen Alzheimer’s trial

Eisai Co., Ltd. and Biogen Inc. have announced positive topline results from Eisai’s large global phase 3 confirmatory Clarity AD clinical trial of lecanemab to treat mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) and mild AD (collectively known as early AD) with confirmed presence of amyloid pathology in the brain. Lecanemab is an […]

September 29, 2022 - 6 minutesmins - By Jim Cornall

News and Trends 22 Sep 2022

Research identifies new treatment target for CNS injury and neurological disease

Researchers in Birmingham in the U.K. have identified a potential target for drugs to treat long-term neurological conditions like Alzheimer’s Disease and foster nerve regeneration in central nervous system injuries. The research, published last week in Science Advances, is part of a workstream exploring the signaling pathways that respond to DNA damage, which is seen […]

September 22, 2022 - 3 minutesmins - By Jim Cornall

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us